Overview of the efficacy and most common side effects of treatment with cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors in metastatic breast cancer. (2021). Onkologija, 25(2), 48-53. https://doi.org/10.25670/oi2021-017on